Chronic Tearing Induced by Apremilast

The therapeutic potential of Phosphodiesterase 4 (PDE-4) inhibitors has been studied for various hyperproliferative skin disorders, such as psoriasis and atopic dermatitis. Inhibition of PDE-4 activity leads to elevated levels of intracellular cAMP; this results in anti-inflammatory effects in almost all inflammatory cells.1 Apremilast is an oral PDE-4 inhibitor that is FDA approved for the treatment of psoriatic arthritis in adults as well as patients with moderate to severe plaque psoriasis. The most common adverse reactions to apremilast (≥5%) are diarrhea, nausea, headache, and upper respiratory tract infection.

https://ift.tt/2IKfnai